IADR Abstract Archives
ANTIMICROBIAL ACTIVITY OF NOVEL IN-SITU FORMING IMPLANTS FOR PERIODONTITIS TREATMENT
Objectives: Local antimicrobials are commonly used for periodontal treatment. Recently, novel polymer-based in-situ forming implants (ISFI), with dual antibacterial and anti-inflammatory activity, were developed and showed promising physical properties compared to commercial products available on the market [1]. The risk of premature, accidental loss of the formulations from the site of action can be expected to be substantially reduced. The aim of this study was to assess the respective antibacterial activity of ISFI loaded with chlorhexidine (Chx) and ibuprofen (Ibu) on bacteria isolated from periodontal patients.
Methods: ISFI formulations (%Chx/Ibu: drug-free; 0.5/0.5; 2/2; 8/8) were compared to Chlo-site, a Chx-loaded marketed product, and Chx solutions at predefined concentrations. Bacteria were isolated from patients suffering from periodontitis. Two tests were applied: agar diffusion test (comparing the diameters of the bacterial growth inhibition zones - BGI), and kill-time test [combining 9 ml of broth containing a defined inoculum (105 CFU/ml) with 1 ml ISFI (or Chlo-site) and counting the bacteria after incubation for 1, 2, 3, 6 and 24 hours].
Results: Agar diffusion test All drug-loaded ISFI were effectively limiting bacteria growth. After 48h, BGI ranged from 1.3 to 2.7 cm for ISFI. No substantial difference was found between Chlo-site and ISFI. Interestingly, the effect of the ISFI drug loading was much less pronounced than the effect of the drug concentration of a Chx solution (probably due to the controlled drug-release effect of the ISFI).
Kill-time test: After 24h both ISFI and Chlo-site showed an effective reduction of bacterial count (<1 CFU/ml). Drug-free ISFI did not inhibit the bacterial growth. The overall activity of Chlo-site was lower or equal to Chx/Ibu%: 2/2 ISFI.
Conclusions: The proposed in-situ forming implants do not only offer improved adhesion, they also effectively act against bacteria found in periodontal pockets of patients.
Methods: ISFI formulations (%Chx/Ibu: drug-free; 0.5/0.5; 2/2; 8/8) were compared to Chlo-site, a Chx-loaded marketed product, and Chx solutions at predefined concentrations. Bacteria were isolated from patients suffering from periodontitis. Two tests were applied: agar diffusion test (comparing the diameters of the bacterial growth inhibition zones - BGI), and kill-time test [combining 9 ml of broth containing a defined inoculum (105 CFU/ml) with 1 ml ISFI (or Chlo-site) and counting the bacteria after incubation for 1, 2, 3, 6 and 24 hours].
Results: Agar diffusion test All drug-loaded ISFI were effectively limiting bacteria growth. After 48h, BGI ranged from 1.3 to 2.7 cm for ISFI. No substantial difference was found between Chlo-site and ISFI. Interestingly, the effect of the ISFI drug loading was much less pronounced than the effect of the drug concentration of a Chx solution (probably due to the controlled drug-release effect of the ISFI).
Kill-time test: After 24h both ISFI and Chlo-site showed an effective reduction of bacterial count (<1 CFU/ml). Drug-free ISFI did not inhibit the bacterial growth. The overall activity of Chlo-site was lower or equal to Chx/Ibu%: 2/2 ISFI.
Conclusions: The proposed in-situ forming implants do not only offer improved adhesion, they also effectively act against bacteria found in periodontal pockets of patients.